fosfomycin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 1243 23155-02-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fosfomycin trometamol
  • fosfomycin
  • fosfomycin tromethamine
An antibiotic produced by Streptomyces fradiae.
  • Molecular weight: 138.06
  • Formula: C3H7O4P
  • CLOGP: -0.23
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 70.06
  • ALOGS: -0.47
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 g O
8 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 82 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 192.90 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 31 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.32 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 19, 1996 FDA ZAMBON SPA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 75.34 43.04 17 223 5501 2352344
Enterocolitis 44.31 43.04 8 232 832 2357013

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pathogen resistance 97.40 85.86 15 72 1074 1745620

Pharmacologic Action:

SourceCodeDescription
ATC J01XX01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER ANTIBACTERIALS
Other antibacterials
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Urinary tract infectious disease indication 68566005
Escherichia coli urinary tract infection indication 301011002
Enterococcus Urinary Tract Infection indication
Kidney disease contraindication 90708001 DOID:557
Pseudomembranous enterocolitis contraindication 397683000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.54 acidic
pKa2 5.59 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
UDP-N-acetylglucosamine 1-carboxyvinyltransferase Enzyme INHIBITOR IC50 7 CHEMBL CHEMBL
UDP-N-acetylglucosamine 1-carboxyvinyltransferase 1 Enzyme WOMBAT-PK
UDP-N-acetylglucosamine 1-carboxyvinyltransferase 2 Enzyme WOMBAT-PK
UDP-N-acetylglucosamine 1-carboxyvinyltransferase Unclassified IC50 4.98 CHEMBL

External reference:

IDSource
D005578 MESH_DESCRIPTOR_UI
4024047 VUID
N0000022052 NUI
C0016610 UMLSCUI
D00925 KEGG_DRUG
2N81MY12TE UNII
3014 INN_ID
78964-85-9 SECONDARY_CAS_RN
108720006 SNOMEDCT_US
4550 RXNORM
372534005 SNOMEDCT_US
d04106 MMSL
4024047 VANDF
004467 NDDF
446987 PUBCHEM_CID
CHEBI:28915 CHEBI
DB00828 DRUGBANK_ID
CHEMBL1757 ChEMBL_ID
CHEMBL1200331 ChEMBL_ID
FCN PDB_CHEM_ID
FFQ PDB_CHEM_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Monurol HUMAN PRESCRIPTION DRUG LABEL 1 0456-4300 POWDER 3 g ORAL NDA 15 sections